Many clinical trials do not include enough people from important groups such as racial minorities, ethnic communities, and women. This lack of diversity can cause problems because medical treatments that are tested mostly on certain groups might not work as well or could even be unsafe for others. For example, a medicine tested mainly on men may have different effects when used by women. Without better representation, some groups may continue to face health risks or receive care that does not fully meet their needs. It is important to include a wider variety of people in research to make sure new treatments are safe and effective for everyone regardless of gender or race.
Efforts to improve diversity in clinical trials have been around for decades. One important step was the Civil Rights Act of 1964. This law made it illegal to discriminate against people because of their race, color, religion, national origin, or sex. It applies to hospitals and other medical places that get money from the federal government. Because of this law, these places are required to treat everyone fairly and cannot exclude people from research based on these factors. Even with this rule in place, however, many clinical trials still struggle to include a wide range of participants.
A summary report looked at clinical trials for drugs between 2015 and 2019. It found that non-Hispanic white people made up 78 percent of the participants in U.S. trial sites, even though they only make up about 61 percent of the country’s population. This shows there is a clear imbalance in who takes part in these studies. When some groups are overrepresented and others are left out, it can lead to treatments that do not work as well for everyone.
This imbalance in clinical trials can have real effects on patients and their families. When certain groups are not well represented, doctors may not have enough information about how treatments work for everyone. This can lead to some patients receiving care that is less effective or has unexpected side effects. For families, this means uncertainty and sometimes facing health problems that could have been better managed with more inclusive research. For future research, it highlights the need to include more diverse participants. Without this, new medicines and treatments might only work well for a limited number of people instead of everyone who needs them. Making clinical trials more fair and inclusive is key to improving health outcomes for all communities.
Dinkar Sindhu, CEO of AXIS Clinicals, highlights the importance of diversity in clinical trials, especially when it comes to rare diseases. He explains that having a diverse and fair group of participants is essential because treatments developed from similar groups may not work well for people of different genders, ethnic backgrounds, ages, or abilities. Sindhu warns that without proper representation, many patient groups could be left behind. “Without representation that mirrors real‑world patient communities, we risk producing therapies that leave many groups unserved or misunderstood,” he says. This shows how important it is for researchers to include everyone to make sure new treatments can help all patients, not just a few.
Over the past thirty years, improving diversity in clinical trials has become a key focus for several federal agencies and organizations. Groups like the National Institutes of Health Office of Research on Women’s Health and the Office of Women’s Health have worked to ensure that women are better represented in research. These agencies have introduced programs which require researchers to include women and minority groups in clinical studies whenever possible. Additional guidance documents have been issued encouraging the enrollment of diverse populations in clinical trials. While these steps have helped raise awareness and improve participation, more work is needed to close the gaps completely. Achieving true diversity in clinical trials will require ongoing commitment, collaboration, and new strategies to ensure that all patient groups are fairly represented in medical research.
